| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
In the last three months, 18 analysts have published ratings on Crinetics Pharmaceuticals (NASDAQ:CRNX), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 7 | 11 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 2 | 0 | 0 | 0 |
| 2M Ago | 3 | 3 | 0 | 0 | 0 |
| 3M Ago | 3 | 5 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $62.78, a high estimate of $97.00, and a low estimate of $48.00. This upward trend is apparent, with the current average reflecting a 24.89% increase from the previous average price target of $50.27.
The analysis of recent analyst actions sheds light on the perception of Crinetics Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Josh Schimmer | Cantor Fitzgerald | Maintains | Overweight | $65.00 | - |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $60.00 | - |
| Jonathan Wolleben | JMP Securities | Maintains | Market Outperform | $80.00 | - |
| Yasmeen Rahimi | Piper Sandler | Raises | Overweight | $97.00 | $56.00 |
| Jonathan Wolleben | JMP Securities | Maintains | Market Outperform | $80.00 | - |
| Leland Gershell | Oppenheimer | Raises | Outperform | $55.00 | $54.00 |
| Jonathan Wolleben | JMP Securities | Raises | Market Outperform | $80.00 | $60.00 |
| Douglas Tsao | HC Wainwright & Co. | Raises | Buy | $60.00 | $50.00 |
| Lina Kaminski | JonesTrading | Raises | Buy | $56.00 | $52.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $50.00 | - |
| Leland Gershell | Oppenheimer | Raises | Outperform | $54.00 | $48.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $50.00 | - |
| Douglas Tsao | HC Wainwright & Co. | Raises | Buy | $50.00 | $42.00 |
| David Lebovitz | Citigroup | Announces | Buy | $68.00 | - |
| Josh Schimmer | Cantor Fitzgerald | Raises | Overweight | $65.00 | $50.00 |
| Jonathan Wolleben | JMP Securities | Raises | Market Outperform | $60.00 | $50.00 |
| Leland Gershell | Oppenheimer | Raises | Outperform | $48.00 | $46.00 |
| Brian Skorney | Baird | Raises | Outperform | $52.00 | $45.00 |
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Crinetics Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Crinetics Pharmaceuticals analyst ratings.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, Crinetics Pharmaceuticals faced challenges, resulting in a decline of approximately -76.11% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Crinetics Pharmaceuticals's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -10457.81%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Crinetics Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -9.47%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Crinetics Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -8.3%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.06.
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: CRNX
